Fig. 2From: Molecular and clinicopathologic features of gliomas harboring NTRK fusionsRepresentative T1 postcontrast MRI images of a pediatric NTRK-fused glioma treated with targeted TRK inhibitor therapy. (a) Recurrent/residual tumor along the patient’s resection cavity (arrow) demonstrated (b) radiologic response to larotrectinib (arrow)Back to article page